Journal: Cardiovascular Research

Article Title: The sympathetic nervous system exacerbates carotid body sensitivity in hypertension

doi: 10.1093/cvr/cvac008

Figure Lengend Snippet: ES (30 Hz, 2 ms, 10 V) of the SCG leads to chemoreflex hyperreflexia of the sympathetic nerve response in both Wistar and SH rat (SHR) strains. ( A ) Schematic of the working heart-brainstem preparation (WHBP) showing cannulation of the ICA for drug infusions into the CB, and ES of SCG. Enhanced integrated CSN (∫CSN) discharge reveals a sensitizing effect of ES-SCG on the CB. ( B ) tSNA (raw and integrated waveform) during chemoreflex activation before and after ES in Wistar and ( C ) SHR. ( D ) Group data of ES of the SCG on the chemoreflex-evoked sympathoexcitation of Wistar ( n = 6) vs. ( E ) SHR ( n = 6). ( F ) The slope of linear regression between rat strains shows no difference in the gain of chemoreflex sensitization following ES of the SCG. ( G ) tSNA (raw and integrated waveform) during chemoreflex activation before and after ES and repeated after injection of tamsulosin (50 µL, 1 mmol/L) into ICA of a Wistar rat. ( H ) Tamsulosin blocked the sensitizing effect of ES-SCG on the CB-evoked sympathoexcitation ( n = 6). Chemoreflex was evoked via intra-aorta injection of NaCN (0.4 µg/µL; 50 µL). Data analysed using paired Student’s t -test and mixed-effects model from ES onwards; * P < 0.05 and ** P < 0.01. Note: the reduced number of data points in ( D and E ) reflects the loss of high-quality recordings in five preparations.

Article Snippet: We injected into the ICA either 40 μL of prazosin (1 mmol/L in saline pH = 3, i.e. 17 μg bolus, Sigma-Aldrich, Australia,— n = 10), an inverse agonist of α 1 -adrenoceptors, or 50 μL of tamsulosin (1 mmol/L in saline, i.e. 22 μg bolus, Tocris Bioscience, UK,—RDS305010— n = 6).

Techniques: Activation Assay, Injection

Journal:

Article Title: AP1 Regulation of Proliferation and Initiation of Apoptosis in Erythropoietin-Dependent Erythroid Cells

doi:

Figure Lengend Snippet: The presence of a dominant negative AP1 mutant blocks apoptosis in HCD57 cells. (A) Western blot analysis of 40 μg of nuclear protein from HCD57, HCD57-TAM-67, and HCD57 cells transfected with vector alone (HCD57-NEOR), using an anti-c-Jun antibody. Upper and lower arrows indicate the presence of the c-Jun and TAM-67 proteins, respectively. (b and c) Growth and survival properties of HCD57 and HCD57-TAM-67 cells exposed to EPO. (b) Proliferative response of HCD57 and HCD57-TAM-67 cells to EPO. Cells were cultured in the absence or presence of 1 U of EPO/ml. Data are indicated as percentages of the starting number of cells. ⧫, HCD57 cells cultured in EPO; ▴, HCD57-TAM-67 cells cultured in EPO; ▪, HCD57 cells cultured in the absence of EPO; ×, HCD57-TAM-67 cells cultured in the absence of EPO for 0, 24, 48, 72, and 96 h. Data are indicated as percentages of the starting number of cells. (d) Prevention of apoptosis by TAM-67 in HCD57 cells. Cells were cultured in the presence of EPO (lanes A to C and G to I) or in the absence of cytokine (lanes D to F and J to L) for the number of hours indicated. Ten micrograms of genomic DNA from HCD57 (lanes A to F) and HCD57-TAM-67 (lanes G to L) cells was resolved on a 2.25% agarose gel. Arrow indicates 100-bp marker.

Article Snippet: The presence of the TAM-67 message was verified by Northern blot analysis, and protein expression was verified by Western blot analysis using an anti-c-Jun antibody (Santa Cruz Biotechnology).

Techniques: Dominant Negative Mutation, Mutagenesis, Western Blot, Transfection, Plasmid Preparation, Cell Culture, Agarose Gel Electrophoresis, Marker

Journal:

Article Title: AP1 Regulation of Proliferation and Initiation of Apoptosis in Erythropoietin-Dependent Erythroid Cells

doi:

Figure Lengend Snippet: Bcl-XL levels are maintained in EPO-deprived HCD57-TAM-67 cells. Total cellular proteins were isolated from HCD57 and HCD57-TAM-67 cells and were subjected to Western blot analysis with an anti-Bcl-XL antibody. Positions of molecular weight markers are indicated at the left. Arrows indicate the presence of the Bcl-XL protein. Bcl-XL levels decreased 72 h following EPO withdrawal in HCD57 cells (top) but were unchanged in HCD57-TAM-67 cells deprived of EPO for 96 h (bottom).

Article Snippet: The presence of the TAM-67 message was verified by Northern blot analysis, and protein expression was verified by Western blot analysis using an anti-c-Jun antibody (Santa Cruz Biotechnology).

Techniques: Isolation, Western Blot, Molecular Weight

Journal: BMC Geriatrics

Article Title: Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing

doi: 10.1186/s12877-022-03415-7

Figure Lengend Snippet: Summary of characteristics of included studies

Article Snippet: Welk et al. (2015) [ ] CA , Retrospective cohort study , Tamsulosin, silodosin, alfuzosin vs. no alpha-blocker treatment , Alpha-blocker initiation: n = 147,084 No initiation: n = 147,084 , Age ≥ 66 y Alpha-1 antagonist cohorts: Initiation of first treatment with tamsulosin, silodosin, or alfuzosin Non-alpha-1 antagonist cohort: Unexposed to alpha-blocker Matched on age, residential status, prior fractures, use of 5α-reductase inhibitors , 90 days , Primary outcome: hospitalization for a fall or fracture within 90 days after initiation of alpha-blocker therapy Secondary outcomes: hypotension, head trauma , Institute for Clinical Evaluative Sciences (Ontario Ministry of Health and Long-Term Care).

Techniques: Data-independent acquisition, Medications, Biomarker Discovery

Journal: BMC Geriatrics

Article Title: Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing

doi: 10.1186/s12877-022-03415-7

Figure Lengend Snippet: Meta-analysis on the change in IPSS tamsulosin 0.2 mg vs. naftopidil 50 mg pre to post administration

Article Snippet: Welk et al. (2015) [ ] CA , Retrospective cohort study , Tamsulosin, silodosin, alfuzosin vs. no alpha-blocker treatment , Alpha-blocker initiation: n = 147,084 No initiation: n = 147,084 , Age ≥ 66 y Alpha-1 antagonist cohorts: Initiation of first treatment with tamsulosin, silodosin, or alfuzosin Non-alpha-1 antagonist cohort: Unexposed to alpha-blocker Matched on age, residential status, prior fractures, use of 5α-reductase inhibitors , 90 days , Primary outcome: hospitalization for a fall or fracture within 90 days after initiation of alpha-blocker therapy Secondary outcomes: hypotension, head trauma , Institute for Clinical Evaluative Sciences (Ontario Ministry of Health and Long-Term Care).

Techniques:

Journal: BMC Geriatrics

Article Title: Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing

doi: 10.1186/s12877-022-03415-7

Figure Lengend Snippet: Meta-analysis of the change in IPSS: tamsulosin 0.2 mg pre to post administration

Article Snippet: Welk et al. (2015) [ ] CA , Retrospective cohort study , Tamsulosin, silodosin, alfuzosin vs. no alpha-blocker treatment , Alpha-blocker initiation: n = 147,084 No initiation: n = 147,084 , Age ≥ 66 y Alpha-1 antagonist cohorts: Initiation of first treatment with tamsulosin, silodosin, or alfuzosin Non-alpha-1 antagonist cohort: Unexposed to alpha-blocker Matched on age, residential status, prior fractures, use of 5α-reductase inhibitors , 90 days , Primary outcome: hospitalization for a fall or fracture within 90 days after initiation of alpha-blocker therapy Secondary outcomes: hypotension, head trauma , Institute for Clinical Evaluative Sciences (Ontario Ministry of Health and Long-Term Care).

Techniques:

Journal: BMC Geriatrics

Article Title: Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing

doi: 10.1186/s12877-022-03415-7

Figure Lengend Snippet: Meta-analysis on the change in QoL-score tamsulosin 0.2 mg vs. naftopidil 50 mg pre to post administration

Article Snippet: Welk et al. (2015) [ ] CA , Retrospective cohort study , Tamsulosin, silodosin, alfuzosin vs. no alpha-blocker treatment , Alpha-blocker initiation: n = 147,084 No initiation: n = 147,084 , Age ≥ 66 y Alpha-1 antagonist cohorts: Initiation of first treatment with tamsulosin, silodosin, or alfuzosin Non-alpha-1 antagonist cohort: Unexposed to alpha-blocker Matched on age, residential status, prior fractures, use of 5α-reductase inhibitors , 90 days , Primary outcome: hospitalization for a fall or fracture within 90 days after initiation of alpha-blocker therapy Secondary outcomes: hypotension, head trauma , Institute for Clinical Evaluative Sciences (Ontario Ministry of Health and Long-Term Care).

Techniques:

Journal: BMC Geriatrics

Article Title: Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing

doi: 10.1186/s12877-022-03415-7

Figure Lengend Snippet: Meta-analysis of the change in QoL-Score tamsulosin 0.2 mg pre to post administration

Article Snippet: Welk et al. (2015) [ ] CA , Retrospective cohort study , Tamsulosin, silodosin, alfuzosin vs. no alpha-blocker treatment , Alpha-blocker initiation: n = 147,084 No initiation: n = 147,084 , Age ≥ 66 y Alpha-1 antagonist cohorts: Initiation of first treatment with tamsulosin, silodosin, or alfuzosin Non-alpha-1 antagonist cohort: Unexposed to alpha-blocker Matched on age, residential status, prior fractures, use of 5α-reductase inhibitors , 90 days , Primary outcome: hospitalization for a fall or fracture within 90 days after initiation of alpha-blocker therapy Secondary outcomes: hypotension, head trauma , Institute for Clinical Evaluative Sciences (Ontario Ministry of Health and Long-Term Care).

Techniques:

Journal: BMC Geriatrics

Article Title: Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing

doi: 10.1186/s12877-022-03415-7

Figure Lengend Snippet: Meta-analysis on the occurrence of ADEs while treatment with tamsulosin 0.2 mg or naftopidil 50 mg

Article Snippet: Welk et al. (2015) [ ] CA , Retrospective cohort study , Tamsulosin, silodosin, alfuzosin vs. no alpha-blocker treatment , Alpha-blocker initiation: n = 147,084 No initiation: n = 147,084 , Age ≥ 66 y Alpha-1 antagonist cohorts: Initiation of first treatment with tamsulosin, silodosin, or alfuzosin Non-alpha-1 antagonist cohort: Unexposed to alpha-blocker Matched on age, residential status, prior fractures, use of 5α-reductase inhibitors , 90 days , Primary outcome: hospitalization for a fall or fracture within 90 days after initiation of alpha-blocker therapy Secondary outcomes: hypotension, head trauma , Institute for Clinical Evaluative Sciences (Ontario Ministry of Health and Long-Term Care).

Techniques:

Journal: BMC Geriatrics

Article Title: Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing

doi: 10.1186/s12877-022-03415-7

Figure Lengend Snippet: Meta-analysis on the association of tamsulosin treatment vs. no medication and the incidence of dementia

Article Snippet: Welk et al. (2015) [ ] CA , Retrospective cohort study , Tamsulosin, silodosin, alfuzosin vs. no alpha-blocker treatment , Alpha-blocker initiation: n = 147,084 No initiation: n = 147,084 , Age ≥ 66 y Alpha-1 antagonist cohorts: Initiation of first treatment with tamsulosin, silodosin, or alfuzosin Non-alpha-1 antagonist cohort: Unexposed to alpha-blocker Matched on age, residential status, prior fractures, use of 5α-reductase inhibitors , 90 days , Primary outcome: hospitalization for a fall or fracture within 90 days after initiation of alpha-blocker therapy Secondary outcomes: hypotension, head trauma , Institute for Clinical Evaluative Sciences (Ontario Ministry of Health and Long-Term Care).

Techniques:

Journal: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences

Article Title: Measurement of tamsulosin in human serum by liquid chromatography–tandem mass spectrometry ☆

doi: 10.1016/j.jchromb.2013.04.020

Figure Lengend Snippet: Chemical structures and proposed fragmentation patterns for analyte and internal standard. Accurate masses shown for analyte quantifier and qualifier ions were confirmed to within 10 ppm of their theoretical monoisotopic mass. (A) Structure and proposed fragmentation pattern for tamsulosin. (B) Structure and proposed fragmentation for d9-finasteride. (C) Proposed mechanism for fragmentation of d9-finasteride into quantifier ion. From the charged radical parent ion a single deuterium shifts in a concerted transfer of 2 electrons from the deuterated tert -butyl amine to the amide nitrogen with loss of neutral d8-2-methylpropene (shown). A single electron radical transfer is also possible.

Article Snippet: For method application, serum was collected from 3 male subjects who had received at least 3 months of treatment with tamsulosin MR 0.4 mg daily (Synthon Hispania, Sant Boi de Llobregat, Spain).

Techniques:

Journal: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences

Article Title: Measurement of tamsulosin in human serum by liquid chromatography–tandem mass spectrometry ☆

doi: 10.1016/j.jchromb.2013.04.020

Figure Lengend Snippet: Summary of key characteristics of published assays to quantify tamsulosin from plasma or serum.

Article Snippet: For method application, serum was collected from 3 male subjects who had received at least 3 months of treatment with tamsulosin MR 0.4 mg daily (Synthon Hispania, Sant Boi de Llobregat, Spain).

Techniques: Clinical Proteomics, Solvent

Journal: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences

Article Title: Measurement of tamsulosin in human serum by liquid chromatography–tandem mass spectrometry ☆

doi: 10.1016/j.jchromb.2013.04.020

Figure Lengend Snippet: (A) d9-Finasteride DQ135 13 C NMR (126 MHz, CDCl3) δ = C-20 : 172.29, C-3 : 167.09, C-1 : 151.71, C-2 : 122.30, C-5 : 59.56, C-14 : 57.29, C-17 : 55.48, C-22 : 50.63, C-9 : 47.47, C-13 : 43.97, C-10 : 39.27, C-12 : 38.16, C-8 : 35.22, C-7 : 29.33, C-6 : 25.55, C-15 : 24.15, C-16 : 23.12, C-11 : 21.13, C-18 : 13.13, C-19 : 11.76. Assignation was carried out based on previously published data . A reference sample of finasteride scanned on the same instrument gave the same signals, apart from the presence of the intense tert -butyl CH3 signal at 28.7 ppm. cps, counts per second. (B) Product ion spectra for protonated tamsulosin in electrospray ionisation mode, with m / z 228 and 200 selected as quantifier and qualifier ions respectively. (C) Product ion spectra for protonated d9-finasteride in electrospray ionisation mode, with m / z 318 and 314 selected as quantifier and qualifier ions respectively. Product ion spectra for both tamsulosin and d9-finasteride were collected under the following conditions: declustering potential 119 V, collision energy 35 V, cell exit potential 16 V.

Article Snippet: For method application, serum was collected from 3 male subjects who had received at least 3 months of treatment with tamsulosin MR 0.4 mg daily (Synthon Hispania, Sant Boi de Llobregat, Spain).

Techniques:

Journal: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences

Article Title: Measurement of tamsulosin in human serum by liquid chromatography–tandem mass spectrometry ☆

doi: 10.1016/j.jchromb.2013.04.020

Figure Lengend Snippet: (A) Representative mass chromatograms of quantifier mass transitions for analyte, tamsulosin, 20 ng/mL (upper panel) and internal standard, d9-finasteride, 10 ng/mL (lower panel) from spiked extracted serum. (B) Representative mass chromatograms of tamsulosin (quantified as 17.1 ng/mL; upper panel) extracted from a patient sample enriched with internal standard, d9-finasteride (10 ng/mL; lower panel). The patient had received tamsulosin (0.4 mg daily) for 90 days. (C) To assess specificity, the method was applied to serum from patients not receiving tamsulosin ( n = 3) with representative chromatograms shown (mass transition of tamsulosin (upper panel), d9-finasteride lower panel)). cps, counts per second.

Article Snippet: For method application, serum was collected from 3 male subjects who had received at least 3 months of treatment with tamsulosin MR 0.4 mg daily (Synthon Hispania, Sant Boi de Llobregat, Spain).

Techniques:

Journal: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences

Article Title: Measurement of tamsulosin in human serum by liquid chromatography–tandem mass spectrometry ☆

doi: 10.1016/j.jchromb.2013.04.020

Figure Lengend Snippet: Calculated concentration of tamsulosin in patient sample, demonstrating acceptable stability at 10 °C for 24 h (in the autosampler) and at −20 °C for 28 days.

Article Snippet: For method application, serum was collected from 3 male subjects who had received at least 3 months of treatment with tamsulosin MR 0.4 mg daily (Synthon Hispania, Sant Boi de Llobregat, Spain).

Techniques: Concentration Assay